FR2943537B1 - Traitement des nevrites vestibulaires par l'acetyl-l-leucine - Google Patents

Traitement des nevrites vestibulaires par l'acetyl-l-leucine

Info

Publication number
FR2943537B1
FR2943537B1 FR0951944A FR0951944A FR2943537B1 FR 2943537 B1 FR2943537 B1 FR 2943537B1 FR 0951944 A FR0951944 A FR 0951944A FR 0951944 A FR0951944 A FR 0951944A FR 2943537 B1 FR2943537 B1 FR 2943537B1
Authority
FR
France
Prior art keywords
nevitis
vestibular
leucine
acetyl
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0951944A
Other languages
English (en)
Other versions
FR2943537A1 (fr
Inventor
Pierre Fabre
Christophe Przybylski
Anne Sophie Saurel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to FR0951944A priority Critical patent/FR2943537B1/fr
Publication of FR2943537A1 publication Critical patent/FR2943537A1/fr
Application granted granted Critical
Publication of FR2943537B1 publication Critical patent/FR2943537B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR0951944A 2006-09-13 2009-03-25 Traitement des nevrites vestibulaires par l'acetyl-l-leucine Expired - Fee Related FR2943537B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0951944A FR2943537B1 (fr) 2006-09-13 2009-03-25 Traitement des nevrites vestibulaires par l'acetyl-l-leucine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0607992A FR2905600B1 (fr) 2006-09-13 2006-09-13 Traitement des vertiges par l'acetyl-l-leucine.
FR0951944A FR2943537B1 (fr) 2006-09-13 2009-03-25 Traitement des nevrites vestibulaires par l'acetyl-l-leucine

Publications (2)

Publication Number Publication Date
FR2943537A1 FR2943537A1 (fr) 2010-10-01
FR2943537B1 true FR2943537B1 (fr) 2011-05-13

Family

ID=37709503

Family Applications (2)

Application Number Title Priority Date Filing Date
FR0607992A Expired - Fee Related FR2905600B1 (fr) 2006-09-13 2006-09-13 Traitement des vertiges par l'acetyl-l-leucine.
FR0951944A Expired - Fee Related FR2943537B1 (fr) 2006-09-13 2009-03-25 Traitement des nevrites vestibulaires par l'acetyl-l-leucine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR0607992A Expired - Fee Related FR2905600B1 (fr) 2006-09-13 2006-09-13 Traitement des vertiges par l'acetyl-l-leucine.

Country Status (12)

Country Link
US (1) US20090318555A1 (fr)
EP (1) EP2068860A2 (fr)
JP (1) JP2010503658A (fr)
AR (1) AR062784A1 (fr)
AU (1) AU2007297181B2 (fr)
CA (1) CA2663206A1 (fr)
FR (2) FR2905600B1 (fr)
MX (1) MX2009002725A (fr)
NZ (1) NZ576150A (fr)
TW (1) TW200817030A (fr)
WO (1) WO2008032222A2 (fr)
ZA (1) ZA200901452B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
CN109069463B (zh) * 2016-04-19 2024-07-23 内在生物技术有限公司 用于改善运动能力和认知功能的乙酰亮氨酸或其药学上可接受的盐
AU2017308864B2 (en) 2016-08-11 2023-06-01 Intrabio Limited Pharmaceutical compositions and uses directed to lysosomal storage disorders
CA3033564A1 (fr) * 2016-08-11 2018-02-15 Intrabio Limited Acetyle-leucine pour les maladies neurodegeneratives
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
EP3697406A1 (fr) * 2017-10-18 2020-08-26 IntraBio Ltd Agents thérapeutiques pour mobilité et fonction cognitive améliorées et pour le traitement de maladies neurodégénératives et de troubles de stockage lysosomal

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB798680A (en) * 1956-03-30 1958-07-23 Rhone Poulenc Sa Improvements in or relating to the preparation of pharmaceutical compositions
US2941924A (en) * 1956-03-30 1960-06-21 Rhone Poulenc Sa Monoethanolamine salt of alpha-(acetylamino)-isocaproic acid

Also Published As

Publication number Publication date
FR2905600B1 (fr) 2010-01-15
US20090318555A1 (en) 2009-12-24
FR2905600A1 (fr) 2008-03-14
AU2007297181A1 (en) 2008-03-20
FR2943537A1 (fr) 2010-10-01
CA2663206A1 (fr) 2008-03-20
AU2007297181B2 (en) 2013-10-17
EP2068860A2 (fr) 2009-06-17
MX2009002725A (es) 2009-03-25
NZ576150A (en) 2011-11-25
JP2010503658A (ja) 2010-02-04
WO2008032222A3 (fr) 2008-05-02
WO2008032222A2 (fr) 2008-03-20
AR062784A1 (es) 2008-12-03
TW200817030A (en) 2008-04-16
ZA200901452B (en) 2010-04-28

Similar Documents

Publication Publication Date Title
FR20C1014I2 (fr) Traitement de troubles du cycle sommeil-eveil
FR21C1062I1 (fr) Traitement combiné de tumeurs exprimant la cd38
LTPA2016033I1 (lt) Fabri ligos gydymo priemonės
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
EP1876990A4 (fr) Traitement dentaire par l'intermediaire d'elements d'alignement
DK2056807T3 (da) Behandling af inflammatoriske sygdomme
FR2876047B1 (fr) Traitement de polluants par phytolixiviation
PL2049132T3 (pl) Nowe środki do leczenia zaburzeń związanych z osłabionym neuroprzekaźnictwem
BRPI0916125A2 (pt) "dispositivo de tratamento"
ZA200803659B (en) Use of complement pathway inhibitors to treat ocular disease
DK2004204T3 (da) Behandling af neurodegenerative sygdomme med selenat
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
DK1962869T3 (da) Behandling af luftvejssygdomme
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
ATE530175T1 (de) Therapeutische kombination für schmerzhafte medizinische zustände
DE602006009764D1 (de) Terphenylderivate zur Alzheimerbehandlung
PL2056863T3 (pl) Leczenie chorób oczu
MA29097B1 (fr) Composes pour le traitement des infections virales par flaviviridae
FR2943537B1 (fr) Traitement des nevrites vestibulaires par l'acetyl-l-leucine
FI20095600A (fi) Koostumus ihosairauksien hoitoa varten
DK2056858T3 (da) Behandling af lungesygdomstilstande
BRPI0717671A2 (pt) "irrigador dental"
MA28694B1 (fr) Traitement des infections bacteriennes
ATE474574T1 (de) Imidazoazephinonverbindungen
FR2910813B1 (fr) Nouvelle utilisation therapeutique pour le traitement des leucemies

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20150529